(Q43228739)

16 November 2017

title

Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment (English)

1 reference

16 November 2017

1 reference

ChEBI release 2020-05-28

1 reference

William Smith

1

1 reference

16 November 2017

Suzanne Swan

series ordinal

2

1 reference

16 November 2017

Thomas Marbury

series ordinal

3

1 reference

16 November 2017

Herbert Henney

series ordinal

4

1 reference

16 November 2017

publication date

4 December 2009

1 reference

The Journal of Clinical Pharmacology

16 November 2017

published in

1 reference

16 November 2017

volume

50

1 reference

16 November 2017

issue

2

1 reference

16 November 2017

page(s)

151-159

1 reference

4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve.

16 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

Gating-dependent mechanism of 4-aminopyridine block in two related potassium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

Dose comparison trial of sustained-release fampridine in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

Pharmacokinetics of an Immediate‐Release Oral Formulation of Fampridine (4‐Aminopyridine) in Normal Subjects and Patients with Spinal Cord Injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

Atypical presentation of 4-aminopyridine overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

An unusual case of 4-aminopyridine toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

A systematic review of the associations between dose regimens and medication compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

4-Aminopyridine in Patients with Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009344857

21 January 2018

Identifiers

DOI

10.1177/0091270009344857

1 reference

16 November 2017

1 reference